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Effect of PDGF-BB on Human Retinal Pericytes
Matthew Parvus1, Cristian Mercado2, Francisco Elisarraras2, Daniela Gonzalez2, Andrew Tsin
PhD1
1UTRGV School of Medicine, 2University of Texas Rio Grande Valley
Abstract
Background – The majority of ocular conditions seen in patients with diabetic retinopathy are a
result of damage to the retinal vasculature, which leads to microaneurysms, hemorrhage, and
eventually neovascularization. The first step in the pathogenesis of these conditions is derived
from the loss of Human Retinal Pericytes (HRPs), or cells which are essential to the preservation
of the integrity of the retinal vasculature, and PDGF-BB is the primary promotor of growth and
recruitment for HRPs.
Aim - Patients with NPDR produce lower levels of PDGF-BB than in normal conditions, which
could contribute to the loss of pericytes early in diabetic retinopathy. The purpose of this study
is to evaluate the effect of PDGF-BB on HRPs in vitro to determine whether or not the longevity
of the HRPs can be preserved with the intent of contributing to development of therapeutic
interventions for patients with diabetic retinopathy. This is the first PDGF-BB study on its effect
on the viability and longevity of HRPs.
Methods – Three groups of HRPs were treated with three different concentrations of PDGF-BB
which correlate to concentrations found in patients with PDR, NPDR, and normal conditions.
These three concentrations were also compared with a negative control group which was not
treated. After 24 and 48 hours the viable cells were counted by triptan blue measurements. The
results were reported by evaluating viable cells at 24 and 48 hours, growth of each group
between these time periods, and significant growth differences between groups at each time
period. Each group was grown in triplicates and an average from these triplicates was used
during analysis.
Results – Of the results found, three were clinically significant. Pertaining to viability, the NPDR
group was the only one with a significant result at 24 hours. Growth difference analysis was
significant for the PDR group at the 24-hour period. Growth difference between all groups was
significant at the 24 hours mark but not at 48.
Conclusion – Of the results obtained, significant results were only seen at the 24 hours period
which is thought to be a result of the well space not being large enough to accommodate
growth beyond the 24-hour time frame. The finding of a statistically significant difference at 24
hours but not 48 hours further suggests this as the complication as well. That being said,
significant growth difference was seen with the PDR group, which was treated with high levels
of PDGF-BB. This finding is consistent with the hypothesis that PDGF-BB levels encourage the
growth of HRP cells.

Discussion - Previous clinical trials on PDGF-BB inhibitors showed that they did not help patients
with diabetic retinopathy due to the inherent deficiency of HRPs found in these patients. We
anticipate results from this study will support an opposing approach by supplementing PDGFBB, rather than blocking leading to innovative clinical outcomes.

